+15 C°
Traffic jam:   5

Pfizer and BioNTech have applied for a coronavirus vaccine in the U.S.

21 November 2020
2 min.
Pfizer and BioNTech have applied for a coronavirus vaccine in the U.S.

A historic day for science

If the application is approved, a vaccine with a 95% declared efficacy can be used in mid-late December, Pfizer expects. Earlier, experts warned of possible problems with the drug's distribution.

American company Pfizer and German BioNTech have applied for their coronavirus vaccine in the USA.

The CEO of Pfizer Albert Bourla said: "This is a historic day for science and for each of us. It has only been 248 days since we announced our plans to work with BioNTech".

In early November, BioNTech and Pfizer reported that the BNT162b2 vaccine they are developing has shown more than 90% success in trials. Later on, the companies increased their efficiency rating to 95%.

According to Pfizer, the vaccine was highly effective in all groups regardless of age, gender or race. In particular, for people over 65 years of age, the company estimates that the vaccine was 94% effective. At the same time, older people could tolerate the vaccination more easily and less often complained about side effects, added to Pfizer.

After the company announced the high efficacy of its COVID-19 vaccine, the European Union decided to buy 300 million doses of the vaccine. Reuters estimates that the EU could pay €4.6 billion for it at a price of €15.5 ($18.34) per dose. The European Commission representative and Pfizer herself did not disclose the cost of the drug to the agency.

Countries that are waiting to receive Pfizer vaccine will have to build infrastructure from scratch to transport, store and defrost it, Bloomberg said. "We need huge investments and coordination, which only rich countries have, and even they probably only have for the population of large cities", writes the agency.

However, even if countries are able to build the necessary infrastructure, there is still the question of delivering a specific patient especially in areas that are difficult to access. As a result, countries will have to decide whether they are ready for the cost or would rather wait until the end of a vaccine trial that can be stored at minus 20 degrees, Bloomberg says.

Persons1 and Companies4 in the news

Chairman and Chief Executive Officer of Pfizer
1 place
1 place
3 place
Bloomberg L.P.
4 place


Rating companies
56 Mention
55 Mention
52 Mention
52 Mention
Dow Jones
43 Mention
43 Mention
31 Mention


News from GlobalNY.biz is the freshest and most relevant information about high-profile events in the region. The task of the resource's news feed is to convey to readers with maximum accuracy and objectivity information about important events in business, politics, economy, healthcare, culture and other spheres of life in New York.
GlobalNY.biz news is a coverage of economic processes taking place in New York, the latest news of public life, incidents and an overview of political events. New York news is information about the activities of small and medium-sized businesses, the work of housing and communal services and utilities, the implementation of significant projects.
The site's journalists describe not only the life of the region, but also talk about the current state of the US economy. Everything you need to know about innovations in the field of industry and agriculture, economy and power is collected in the "News" section at GlobalNY.biz.
New York news quickly informs the reader, shows the real picture and opens up hot topics. Communication with government structures and business enables us to provide our readers with reliable, information-rich material. The main page of the portal contains the key news of New York!
Alena Potapova

Development Director